Country: Israel
Language: English
Source: Ministry of Health
PROGESTERONE
MERCK SERONO LTD
G03DA04
GEL
PROGESTERONE 8 %W/W
VAGINAL
Required
MERCK SERONO S.A., SWITZERLAND
PROGESTERONE
PROGESTERONE
Treatment of infertility due to inadequete luteal phase. For use during in-vitro fertilisation, where infertility is mainly due to tubal idiopathic or endometriosis linked sterility associated with normal obulatory.
2020-09-30
بناجلا نم ةيرئاد ةكرحب ءاطغلا عزن بجي .كيمسلا فرطلل حطسملا ءزجلا نم لصوملا كسم بجي ءاوهلا نازخ ىلع ةلحرملا هذه يف طغضلا زوجي لا ،لامعتسلإا لبق لجلا برست بنجتل .عيفرلا سكاعملا .كيمسلا فرطلاب دوجوملا لصوملا لاخدإ لصوملا يلخدأ .نيتحوتفمو نيتينثنم نيتبكرلا نوكت ثيحب ءاقلتسلإاب وأ ءارولا ىلإ دانتسلإاب يموق .كمسج كدي سملات نأ ىلإ لبهملا لخادل ديج لكشبو فطلب .لبهملا ىلإ لصوملا نم لجلا ريرحتل كلذو ةدشب لصوملل كيمسلا فرطلا نم ءاوهلا نازخ ىلع يطغضإ قوف نم ً ابيرقت رتم 760 نم رثكأ هردق عافترإ ىلع رضحتسملا لامعتسلإ ةصاخ تاميلعت :رحبلا حطس ىلع ودبي يذلا( كيمسلا فرطلا نم حطسملا ءزجلا يف درفنم بقث ءارجإب يموق ةداح ةادأ ةطساوب ،لصوملل يلخادلاو يجراخلا ءزجلا نيب لكشتملا ءاوهلا طغض ررحي ءارجلإا اذه .لصوملل )ةعاقف لكش .قهاشلا عافترلإا ببسب !كل ةدوزملا لجلا ةيمك نم ريغي لا ءارجلإا اذه . ً اقباس ةلصفملا تاميلعتلا بسحب لامعتسلإا يلصاو كيمسلا فرطلا ىلع يطغضإ .لصوملا يف هئارجإب تمق يذلا بقثلا ىلع كعبصأ يعض ةلاحلا هذه يف لا تنأف ،قلقلل يعاد لا نكلو ،لصوملا يف لجلا نم ةيمك ىقبت دق .لبهملل لجلا ريرحتل كلذو ،لصوملل .بوغرملا يئاودلا رادقملا نيقلتتس تلز لصوملا لامعتسإ دعب .لصوملا يف لجلا نم ةيقبتملا ةليئضلا ةيمكلا كلذ يف امب ،لصوملا يمرب يموق .ة Read the complete document
Page 1 INTERNAL (incl. business partners) Classification: INTERNAL CRINONE ® 8% Progesterone Vaginal Gel. PRESCRIBING INFORMATION 1. NAME OF THE MEDICINAL PRODUCT Crinone® 8% w/w Progesterone Vaginal Gel. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE INGREDIENT mg/dose % w/w Progesterone 90 8.0 Excipient with known effect: Contains Sorbic acid 0.08% w/w (0.9mg/1.125 g dose). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Vaginal gel 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of infertility due to inadequate luteal phase. For use during in-vitro fertilization, where infertility is mainly due to tubal, idiopathic or endometriosis linked sterility associated with normal ovulatory cycles. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Intravaginal application. Treatment of infertility due to inadequate luteal phase One application (1.125g 8% gel) every day, starting after documented ovulation or arbitrarily on the 18 th -21 st day of the cycle. Page 2 INTERNAL (incl. business partners) Classification: INTERNAL Use during in-vitro fertilisation Daily application of Crinone 8% gel should be continued for 30 days if there is laboratory evidence of pregnancy. Paediatric population Not applicable. Older people Not applicable. Method of Administration Crinone is applied directly from the specially designed sealed applicator into the vagina. The applicator should be removed from the sealed wrapper. The twist-off cap should not be removed at this time. 1. The applicator should be gripped firmly by the thick end. It should be shaken down like a thermometer to ensure that the contents are at the thin end. 2. The tab should be twisted off and discarded. 3. The applicator may be inserted while patient is in a sitting position or when lying on her back with the knees bent. The thin end of applicator should be gently inserted well into the vagina. 4. The thick end of the applicator should be pressed firmly to deposit gel. The applicator should be removed and discarded in a wa Read the complete document